New York, August 24, 2022 /PRNewswire/ — GLO Pharma, the parent company of groundbreaking sub-topic skin care brand Ourself, today announced that Brent Sanders to the board of directors. Sanders, who currently serves as Executive Chairman of his company BeautyHealth, will immediately join the Board of Directors.His appointment adds a new seat to GLO Pharma’s Board of Directors, which currently consists of six members and is headed by the Chairman Scott L. Glenn.
Brent Sanders
Mr. Sanders is a respected innovator who brings extensive leadership experience in the biopharmaceutical and medical aesthetic fields to the Board, has led several mergers and acquisitions, and has held multiple leadership positions at prominent global pharmaceutical and healthcare companies. played the role of
from July 2020 To May 2021, Mr. Souders served as President, Chief Executive Officer and Chairman of the Board of Vesper Healthcare Acquisition Corp. (“Vesper”), leading the merger of Vesper and The HydraFacial Company to become The Beauty Health Company. He serves as executive chairman. Previously, he served as CEO and President of Allergan plc (“Allergan”), best known as the manufacturer of Botox. July 2014 To May 2020and played a leading role in AbbVie’s acquisition of Allergan. He also served on Allergan’s board of directors. July 2014 To May 2020and as its chairman October 2016 To May 2020.
Mr. Sanders previously served as Chief Executive Officer and President of Forest Laboratories, Inc. (“Forest”) and later as CEO of pharmaceutical company Actavis following its acquisition of Forest. Sanders then negotiated a merger of Actavis and Allergan, which ended on October 12, 2018. $70.5 billionMr. Sanders also served as Chief Executive Officer of Bausch + Lomb, one of the world’s leading eye care companies, overseeing the acquisition of the company by Valiant Pharmaceuticals in 2013. At the company, he led the company and his merger with Merck & Co., the acquisition of Organon BioSciences. He is the founder of SPAC Vesper Healthcare Acquisition and currently serves on the boards of BridgeBio Pharma, Inc. and Cisco (NASDAQ: CSCO).
“Mr Sanders’ experience in scaling and transforming the biopharmaceutical and medical aesthetics business, first at Allergan and now at the Beauty Health Company, makes him an invaluable asset to the GLO Pharma Board of Directors. It’s happening,” said the chairman. Scott Glenn“In building a roadmap for our consumer brand Ourself product offerings and topical alternatives to medical procedures, Brent brings incredible insight to the conversation. It’s time to develop new innovations in the wrinkle relief category in the near future.”
The appointment follows the recent announcement of Rothy’s CFO. Dana Quanbeck Joined GLO Pharma’s Board of Directors to launch Ourself, GLO Pharma’s first consumer brand February 2022WE SUPPORT OURSELVES $40 million It is funded by investors such as Lightspeed Venture Partners, First Round Capital and Glenn.
Media contact:
Factory PR // Liz Hill
[email protected]
About Grow Pharma:
GLO Pharma is a biotechnology company dedicated to developing innovative approaches to beauty and aesthetics. Founded in 2018 by Scott Glenn Lauren Otsuki, an innovator in the biotechnology field for over 20 years. Mr. Glenn and Mr. Otsuki, along with a number of pharmaceutical companies aimed at solving the most difficult medical problems such as infertility, diabetes, cardiovascular disease, and cancer, are professional skin care companies, Alastin his skin care and Established and developed Skin Medica. In 2022, GLO Pharma will launch its first consumer brand, Ourself, as his first-ever Subtopical Skincare System™, using biotechnology to bridge the gap between traditional skin care products and clinical procedures. .
Source GLO Pharma
